Genematrix

진매트릭스 · 109820

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$24.6M (₩33.9B)

Overview

Genematrix develops diagnostic test kits that detect infectious diseases, including sexually transmitted infections, tuberculosis, human papillomavirus, respiratory infections, and acute gastroenteritis, by analysing genetic material from a patient sample.

Its products are used in clinical and laboratory settings, and it also has vaccine and cancer-immunotherapy programmes in development. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company's core commercial business centres on its NeoPlex product line, which can test for multiple pathogens simultaneously in a single run using proprietary molecular-detection technologies it has developed in-house.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$7.7M
▲ +6.2% YoY
Operating profit · FY2025
−US$492.1K
Loss narrowed
Net income · FY2025
−US$1.3M
Loss narrowed

Revenue

  • FY2023US$7.1M
  • FY2024US$7.3M
  • FY2025US$7.7M

Operating profit

  • FY2023−US$1.8M
  • FY2024−US$1.2M
  • FY2025−US$492.1K

Net income

  • FY2023−US$648.5K
  • FY2024−US$2.7M
  • FY2025−US$1.3M

Key ratios (FY2025)

ROE
-10.5%
Debt/Eq
56.1%
Op. margin
-6.4%
Net margin
-17.2%
Rev. YoY
▲ +6.2%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.